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Abstract- Retinal vein occlusion (RVO) is a common retinal vascular occlusive disorder and is associated 
with a variety of systemic risk factors. The aim of this study was to investigate whether the underlying 
diseases were evaluated and managed appropriately by ophthalmologists. We performed a study of 1344 
patients with retinal vein occlusion (RVO). Patients were evaluated with a questionnaire including ten closed 
questions to determine whether ophthalmologists evaluated and informed their patients about the underlying 
systemic diseases. None of the patients’ homocysteine levels were measured. Only a small percentage of the 
patients were asked about the history of thrombotic diseases or family history of thrombotic diseases. We 
believe that most ophthalmologists are still not entirely convinced of their responsibility of managing the 
underlying predisposing factors of RVO. Ophthalmologists should either manage or engage other healthcare 
providers in the management of RVO to guarantee the patient the best care.  
© 2016 Tehran University of Medical Sciences. All rights reserved.  
Acta Med Iran, 2016;54(11):731-736. 
 




Retinal vein occlusion (RVO) is by far the most 
common retinal vascular occlusive disorder and is 
usually associated with a visual loss of variable degree 
(1). CRVO is the second most frequent retinal vascular 
disease causing visual loss after diabetic retinopathy (2). 
The clinical manifestations of CRVO are associated with 
venous congestion, which leads to optic disc swelling, 
ischemia, widespread intra-retinal hemorrhage, and 
macular edema (3,4). RVO is a relatively frequent 
disease that may be associated with many different 
systemic diseases (5). 
Most patients with RVO are middle aged to elderly 
(1,2), and more than half have relation with 
cardiovascular disease (CVD) (6,7). Previous reports 
have revealed an increased risk of RVO in patients with 
hypertension, (5,8-11) diabetes mellitus, (6,11) 
dyslipidemia, (1,12) CVD (1,8) and open-angle 
glaucoma (4,9-11,13). Although RVO is common in 
elderly, with 51% of cases happening in patients older 
than 65 years, (12) RVO can also be detected in young 
adults (14). There is a controversy in literature about the 
exact risk factors and pathogenesis of RVO in younger 
patients, most of whom are otherwise healthy. Due to 
the occurrence of RVO in younger patients, several 
predisposing risk factors of thrombophilic abnormalities 
have recently been observed in greater details. Published 
reports on coagulation abnormalities in RVO patients 
have reported association of increased risk of RVO with 
deficiency of protein C, protein S, (15) elevated 
fibrinogen levels (16), antithrombin III, (9,13) and other 
possible etiologies include Behcet disease, (12) 
antiphospholipid syndrome (3,12) and 
hyperhomocysteinaemia (4,12). 
Central retinal vein occlusion (CRVO) was 
correlated with an increase in mortality (17) compared 
with controls that attributed statistically to 
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cardiovascular disorders. Therefore, RVO presentation 
should trigger the evaluation of glaucoma and 
cardiovascular risk factors. Patients with cardiovascular 
disorders should be treated adequately with referral of 
patients who are not already being treated by a primary 
care physician (1,14). 
The purpose of this survey was to investigate 
whether the respective underlying diseases of patients 
with RVO were evaluated and managed appropriately by 
ophthalmologists.  
 
Materials and Methods 
 
This cross-sectional study involved patients who 
were diagnosed and treated for retinal vein occlusion 
between January 1, 2009, and December 31, 2013 
(Table 1). The study was approved by Ethics committee 
in ophthalmology department review board. The 
diagnosis of RVO was made based on clinical 
examination by the treating ophthalmologist. The 
patients with RVO were evaluated with a questionnaire 
between 1 and 4 years after their first clinical visit. 
Fundus photographs, fundus fluorescein angiograms, 
and written records of patients who were registered and 
examined at the institution with the diagnosis of RVO 
were reviewed. The diagnosis of RVO was made based 
on the following criteria: branch retinal vein 
compression at an arteriovenous crossing outside the 
optic disc, cotton wool spots, intra-retinal hemorrhage, 
upstream venous congestion, edema, and vein-to-vein 
collaterals with adjacent branch veins in the absence of 
similar changes in the surrounding venous drainage 
units. In order to decrease the risk of recall bias, 3 
sources (questionnaire, the medical record of hospital 
admission, and medical record of an office visit) were 
used for data collection. It was then assessed if the 
ophthalmologists had ordered cardiovascular or other 
risk factors work up from the medical notes. It was also 
assessed if the patients were referred to a physician for 
the management of the medical condition. Ten closed 
questions were chosen by the Ophthalmology Board of 
our university. Questions that had not been used 
previously were tested cognitively in the context of a 
complete questionnaire on a sample of patients in the 
age group specified for the survey. A pilot study was 
made on the complete baseline questionnaire before 
being finalized. The questionnaire was designed to 
determine whether ophthalmologists whether they 
evaluate background risk factors and cardiovascular 
work up and inform their patients about the underlying 
disorder. The patients or their next of kin (who were 
listed in the medical records) were contacted by phone, 
and the surveys (the questionnaires) were completed by 
interview. When the interviewers were not able to 
establish contact with the patient after 5 times tried over 
weeks or if the patient was dead and his/her relative 
could not give adequate data, the patient was excluded 
from the study. Data was analyzed in SPSS version 11 
(SPSS Inc., Chicago, IL, USA). All data were 
summarized using descriptive statistics (mean [SD], the 




A total of 1344 patients were diagnosed to have 
RVO during the study period. Patients’ ages ranged 
from 27 to 90 years with a mean age of 65.9 years. 
81.1% of cases were older than 60 years (P=0.013). 
There were more women (56.2%) than men (43.8%) 
(P=0.14) in the study (Table 1). 
 
Table1. Baseline demographic features of the enrolled patients 
Parameters Number of patients (%) P.value 
 CRVO* BRVO** Total  
Number of patients 495 (36.8%) 849(63.2%) 1344 (100%) 0.32 
Male (%): Female (%) 256(51.8%): 239(48.2%) 333(39.3%): 516(61.7%) 589(43.8%):755(56.2%) 0.14 
Mean age (year) 63.4 67.3 65.9 0.24 
Age range (No.)  27-84 31-90 27-90 0.16 
0-60 96(19.4%) 158(18.6%) 254(18.9%) 0.09 
60+ 399(80.6%) 691(81.4%) 1090(81.1%) 0.11 
Total 495(100%) 849(100%) 1344(100%) 0.21 
* CRVO: Central retinal vein occlusion 
** BRVO: Branch retinal vein occlusion 
 
 
Right, eyes (46.7%) and left eyes (37.5%) were 
nearly equally affected. Both eyes were involved in 
15.8% of subjects. BRVO was more common (63.2%) 
than CRVO (36.8%) (P=0.32). The supratemporal 
branch was involved in most BRVO subjects (63.3%) 
and macula was involved in only 2.1 % of the subjects 
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(Table 2).  
4% of patients were checked for blood pressure by 
their ophthalmologists (Table 3). Information pertaining 
to comorbid conditions and RVO risk factors was not 
uniformly documented in the medical records. None of 
the patients’ homocysteine levels were measured. Full 
blood count, urea, and electrolytes evaluation were 
scheduled to be performed as an outpatient procedure in 
8.4% of patients older than 60 years old (Table 3). Only 
a small percentage of the patients were asking about the 
history of thrombotic diseases (4%) or family history of 
thrombotic diseases (1%). (Table 3) A total of 9.5% of 
patients have referred patients to internists or 
cardiologists for hypertension and cardiovascular work 
up. Of the patients who visited the hospital, only 8.3% 
were informed about underlying disease (Table 3). 
 
Table 2. Pattern of retinal vein occlusion-diagnosis/laterality by subjects 
Pattern Bilateral eyes Left eye Right eye Total 
BRVO* 
Superotemporal 90(10.6%) 240(28.3%) 208(24.5%) 537(63.2%) 
Inferotemporal 34(4%) 93(10.9%) 109(12.9%) 236(27.8%) 
Hemiretinal 4 (0.5%) 21(2.5%) 15(1.8%) 41(4.8%) 
Macular 5(0.6%) 0(0.0%) 13(1.5%) 18(2.1%) 
Inferonasal 5(0.6%) 4(0.5%) 8(0.9%) 17(2%) 
 Total 138(16.2%) 358(42.2%) 353(41.6%) 849(100%) 
CRVO** 
Non-ischaemic 38(7.7%) 47(9.5%) 196(39.6%) 281(56.8%) 
Ischaemic 37(7.5%) 99(20%) 78(15.8%) 214(43.2%) 
Total 75(15.2%) 146(29.5%) 274(55.3%) 495(100%) 
Total RVO*** (%) 213(15.8%) 504(37.5%) 627(46.7%) 1344(100%) 
* BRVO: Branch retinal vein occlusion 
** CRVO:  Central retinal vein occlusion 
***RVO: Retinal vein occlusion 
 
 
Table 3. Characteristic of survey respondents 
 Age<50 Age>50 Total 
 CRVO BRVO CRVO BRVO  
1. Evaluation of blood pressure (by 
Ophthalmologists) 
0.9% 1.1% 2.1% 2.4% 4% 
2. Evaluation of lipid profile  0.6% 1% 2.9% 3.2% 5% 
3. Evaluation of full blood count, Urea and 
electrolytes 
1.2% 0% 6.1% 2.3% 7% 
4. Evaluation of fasting serum glucose and 
Haemoglobolin A1C 
0.4% 2% 2.2% 3.1% 4.8 
5. Evaluation of homocysteine level 0% 0% 0% 0% 0% 
6. Taking a history of thrombotic diseases 3.5% 0% 2.1% 2% 4% 
7. Taking a  family history of thrombosis diseases 1.8% 0% 0.8% 0% 1% 
8. Referring  patients to internists or cardiologists for 
assessment and management of cardiovascular 
diseases 
8.7% 0% 3.5% 6.1% 9.5% 
9. Informing patients about underlying  disease 4.9 % 2.1% 8.6% 0% 8.3% 
10. Evaluation of hyperecoagulable states (Function 
of Protein C and Protein S level, Anti thrombin III 
level, Antiphospholipid antibodies level, Factor V 
Leiden mutation) 





Our survey of 1344 women and men with a mean 
age of 65.9 years suggests that individuals with RVO 
may be under evaluated and undertreated in our 
institution. Less than 5% of the patients had blood 
pressure measurements, and only a few patients were 
asked to undergo screening tests for systemic risk 
factors such as a hyperlipidemia, diabetes mellitus, 
atherosclerotic vascular disease as baseline 
investigations (full blood count, urea and electrolytes, 
fasting serum glucose and lipids, hemoglobin A1C, 
homocysteine levels); although studies clearly show that 
baseline investigations should be performed for all 
patients older than 50 years with an RVO (5,18-20). 
Dursun et al., revealed increased neutrophil levels and 
decreased lymphocyte levels in patients with RVO and 
concluded that higher neutrophil/lymphocyte ratio 
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(NLR) was associated with the development of RVO. In 
researchers opinion, the NLR may be used as a 
predictive tool for identifying risk for RVO (21). 
The latest meta-analysis of risk factors in RVO 
conducted by Kolar reconfirmed the role of 
hypertension, arteriosclerosis, diabetes mellitus, 
hyperlipidemia, vascular cerebral stroke, blood 
hyperviscosity, and thrombophilia and evidenced that a 
strong risk factor for RVO is the metabolic syndrome 
(hypertension, diabetes mellitus, and hyperlipidemia) 
(22). 
It is important to recognize that RVO may be the 
first indication of hypertension and atherosclerosis 
(18,19,23). Various systemic diseases that cause 
atherosclerosis have been associated with RVO, and 
there is an excess of cardiovascular morbidity and 
mortality on long term follow-up (19,20). These results 
agree with previous long-term investigations where two-
thirds of the deaths in patients presented with RVO were 
due to cardiovascular disease, and the incidence of 
mortality from myocardial infarction was twice the 
expected level. (11,18). In addition RVO patients have a 
greater prevalence of stroke than similarly aged people 
without RVO (5,19). The results from the most recent 
nationwide population-based study conducted by Shih et 
al., suggest that before the diagnosis of RVO, patients 
showed increased risks for hypertension, dyslipidemia, 
diabetes, liver diseases, renal diseases, and 
cerebrovascular diseases. After the diagnosis of RVO, 
patients were at greater risk of developing diabetes, 
peripheral artery disease, and major adverse 
cardiovascular events. Researchers have demonstrated a 
bidirectional association between the risk of 
comorbidities and the diagnosis of RVO in an elderly 
population (24). 
RVO in young patients may be an early marker of 
potentially treatable, controllable and life-threatening 
medical conditions (25). 
A principle step in the management of RVO is to 
inform the patients that they have the atherosclerotic 
vascular disease. The patients with RVO should be 
investigated for the risk factors, and appropriate referral 
should be made to the treating primary care physician. 
Assessment of patients with retinal vein occlusion 
should include a detailed history taking, clinical 
evaluation and laboratory investigations to check for the 
presence of cardiovascular risk factors (25). 
The risk factors need to be appropriately treated so 
as to avoid delayed complications including mortality. 
Appropriate education to the patients regarding the 
underlying condition can improve their awareness about 
the management of the underlying disease. 
It seems that current management options do not 
address the underlying predisposing factors of RVO. 
Instead, they focus on treating ocular complications, 
such as traction retinal detachment from 
neovascularization, macular edema, and vitreous 
hemorrhage. 
Pathogenesis of RVO is a multifactorial process, and 
there is no single factor causes RVO, therefore, the 
management of RVO involves a multidisciplinary 
approach between the ophthalmologist and the general 
physician (26). 
Following a diagnosis of RVO, the United Kingdom 
Royal College of Ophthalmologists recommends that 
treatment of risks known to be associated with all types 
of RVO is necessary. It is the responsibility of the 
ophthalmological team to ensure that medical 
evaluations and management are initiated on the 
diagnosis of RVO. This ensures that the risk of 
occurrence of new occlusions, or the recurrence of RVO 
are reduced (27). 
It is expected that the ophthalmic team will evaluate, 
or arrange for such assessment, of the patient for 
common risk factors of hyperlipidemia and systemic 
hypertension. A referral would be expected to the 
appropriate physician for optimal management. Patients 
should also be referred to the appropriate specialists in 
the relevant field for evaluation and treatment of the 
rarer risk factors (27). 
Hypertension and Cardiovascular Disease are more 
prevalent in patients with BRVO than in those with 
CRVO. More than 64% of RVO patients more than 50 
years are hypertensive, and it is a predominant finding in 
recurrent RVO (88%) (28). 
According to United Kingdom Royal College of 
Ophthalmology Interim guidelines for management of 
retinal vein occlusion, examination of Full blood count, 
ESR or plasma viscosity, urea, electrolytes, creatinine, 
random blood glucose, random cholesterol, HDL 
cholesterol, Plasma protein electrophoresis, and ECG 
suggested in all patients with RVO. When tests for these 
common predisposing factors are negative, 
consideration should be given to ordering additional 
investigations in young patients to detect abnormalities 
of the thrombolytic system, especially in patients with a 
history of thrombosis or a family history of thrombosis 
or in those with bilateral RVO (27). In addition Rehak et 
al., recommended medical investigation of a new patient 
with RVO must include as a first line, examination of 
blood pressure, glucose levels and lipid profile because 
RVO may be a presentation of significant vascular 
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morbidity (29). Hyperlipidemia and 
Hypercholesterolemia are the risk factor for RVO in 
patients under 50-year-old. It is also detected in up to 
50% of older patients. It was revealed that up to71.4% 
of all patients investigated with RVO do have 
hypercholesterolemia (28). 
Younger patients (less than 50 years of age) with 
BRVO usually have underlying systemic conditions 
such as hypertension or hyperlipidemia which should be 
treated appropriately (27,30). 
Those with CRVO present a particular problem in 
evaluation and treatment. Many of these patients will 
have no identifiable underlying cause despite extensive 
evaluation including the specialized investigations like 
Thrombophilia screen, Anti-cardiolipin antibody, lupus 
anticoagulant, C-reactive protein, and Serum ACE 
(13,27).  
Initiating a comprehensive treatment of patients with 
RVO may significantly reduce the incidence, 
recurrences and severity of subsequent complications 
and is necessary to manage the predisposing factors that 
could lead to systemic events (31).  
Obviously, it seems that the most ophthalmologists 
in this study are still not entirely convinced of their 
responsibility and the importance of managing the 
underlying predisposing factors after RVO. In addition, 
availability of both time and resources is restricted for 
ophthalmologists, and in a busy clinic, the possibility of 
under treatment of the underlying cause will increase; 
therefore, ophthalmologists should engage other 
healthcare providers and the hospitals in setting up RVO 
service programs, that they help coordinate this care for 
their patients, and that they contribute to financing the 
coordination program resources. 
Study limitations include the retrospective nature of 
this study and the recall bias which the authors tried to 
reduce by reviewing of patients’ medical record. 
Nevertheless, this is, to date, the first study that 
evaluates the management of RVO by ophthalmologists 
and some useful clinical information can be gained from 
this study. 
The current findings suggest that a majority of 
patients with RVO is caused by highly prevalent 
atherosclerosis risk factors that can be measured in 
routine baseline investigations. Along with a review of 
the articles, a practical approach for the treatment of 
RVO is required, which requires collaboration between 
the ophthalmologists and heath care providers. We 
suggest extensive investigation for systemic diseases in 
RVO cases because management and follow-up can 
prevent morbidity and mortality. 
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